GlobalData on MSN
Synthekine reports initial STK-012 data in lung cancer trial
Synthekine has reported positive initial data from a Phase Ia/Ib trial evaluating STK-012 in first-line, programmed death-ligand 1 (PD-L1)-negative nonsquamous non-small cell lung cancer (NSCLC). In ...
CuraSen Therapeutics, Inc., a biopharmaceutical company developing drug candidates with broad applicability in neurodegenerative and neuropsychiatric diseases, today announced encouraging results from ...
New analysis from landmark Phase 3 PRECISION trial published in the Journal of Hypertension highlights aprocitentan led to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback